Clinical Cancer Research Published a Key Study on the Clinical Validity of OncoMasTR Conducted by Researchers from The Institute of Cancer Research, Royal Marsden Hospital and Queen Mary University of London.
The clinical validation study of OncoMasTR has been published in a peer-reviewed and high impact journal Clinical Cancer Research.
Researchers from Institute of Cancer Research UK, Royal Marsden Hospital, and Queen Mary University found that both OncoMasTR Molecular Score and composite OncoMasTR Risk Score were highly prognostic for early (year 0 to 5) and late distant recurrences (year 5 to 10) in women with early-stage ER-positive breast cancer receiving 5 years’ endocrine therapy and provided significant additional prognostic value beyond clinical treatment score (CTS), Nottingham Prognostic Index (NPI), and Ki67. The study also concluded that as a risk classification tool, the OncoMasTR Risk Score was superior to the Oncotype DX Recurrence Score (RS) in identifying patients at increased risk of distant recurrences.
Des O’Leary, CEO, OncoMark, said, “Publication of such key study by a highly recognised group in translational research is a key milestone in the demonstration of OncoMasTR’s clinical validity and its superiority to the market-leading molecular test”. He added, “In addition to its excellent clinical performance, the OncoMasTR test has been designed to be the most cost-effective test with 3 prognostic genes and 3 reference genes and can be performed using standard laboratory equipment in routine molecular pathology laboratories.”